Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.

“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC

Sign up for our daily newsletter

Abuse-deterrent painkiller fails study goal, drugmaker Acura’s shares fall

August 26, 2013 4:42 pm by | 0 Comments

(Reuters) - Acura Pharmaceuticals Inc said a painkiller made with its abuse-deterrent technology did not show statistically significant results in reducing likability among abusers, sending its shares down 34 percent in after-hours trading.

The study showed that Acura's tablet, Aversion H&A, had a slighter lower measure of liking when compared with the generic hydrocodone/acetaminophen tablet.

The tablet was tested for potential abuse by snorting.

The company said it expects the submission of a marketing approval application to be delayed.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.